A recent study indicates that individuals who come off popular slimming jabs like Mounjaro or Wegovy can put back on lost weight much more quickly than those who end traditional lifestyle programs.
Findings released in a leading medical journal shows that while overweight individuals often shed a large proportion of their body weight while on the medication, the mass is regained at an average rate of nearly a kilo each month once they quit.
"Individuals using such drugs need to be informed of the danger of fast rebound weight gain when the therapy ends," stated lead investigator Dr. Susan Jebb.
Such speed of regain implies a return to pre-treatment weight in about a year and a half.
Comparing Treatments
The analysis, which looked at dozens of studies involving thousands of patients, contrasted the results of the injectable medications with other pills.
Scientists note that people who shed pounds through lifestyle changes alone typically see a more gradual creep back—perhaps 0.1 kg a month—after stopping.
The Reason for the Quick Rebound
Experts believe the mode of action of the injections is key to understanding the amplified rebound.
The injections imitate a body's own chemical called GLP-1, which helps regulate appetite.
"Long-term administration of GLP-1 concentrations far above than normal might result in the body to produce less of its own natural GLP-1, and may also lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this hormone supplement means hunger is no longer kept in check, making overeating much more probable."
An Ongoing Disease?
Health authorities recommend the jabs for individuals with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
Many experts argue that, considering the significant potential of relapse, the treatment is often ongoing.
This opinion is reinforced by drug manufacturers, who note that the results "highlight the long-term nature of obesity," comparing it to managing conditions like hypertension.
Patient Experiences
Individuals who have discontinued the medication report a powerful resurgence of cravings.
"I experienced a trigger that goes on and I was suddenly ravenous," described a patient.
This challenge is worsened if individuals have not established sustainable dietary or behavioural modifications during therapy.
Growing Adoption
Recent estimates suggest that millions of adults in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow.
- Use is greater among women than males.
- The 40s and 50s age group shows the highest level of interest.
- Many access the drugs through private prescriptions rather than public health services.
In conclusion, experts emphasize that while GLP-1 drugs are powerful agents for weight loss, they are not a standalone solution and long-term success relies on combined lifestyle support.
